Defiance ETFs Launched Autism Impact Fund
The investment firm introduced an exchange-traded fund focused on companies providing neurodiversity care services.
Updated on Sept. 30, 2026 in Autism
Live Poll
Would you consider investing in funds that donate a portion of profits to social causes?
On June 1, 2026, Defiance ETFs launched the Defiance Autism Impact ETF, trading under the ticker symbol ASD. The fund tracks the VettaFi Autism Impact Index, which includes 38 global companies involved in neurodiversity care.
Why it matters
The fund strategy targets identified gaps in the current treatment landscape and rising demand for neurodiversity care services. This comes as the projected annual societal cost of autism care in the U.S. was estimated to reach $461 billion by 2025.
The index yielded a 15.84% return year-to-date through August 2026 compared to a three-year annualized return of 18.69%. The ASD ETF maintains a 0.79% gross expense ratio and tracks an index requiring at least $250 million in market capitalization.
The players
Defiance ETFs
This investment firm manages specialized exchange-traded funds targeting niche market sectors and emerging themes.
VettaFi
This data and analytics company provides index solutions and market insights for the financial services industry.
National Institutes of Health
This federal agency is the primary recipient of annual research funding provided under the Autism CARES Act.
The details
The VettaFi Autism Impact Index screens potential holdings based on revenue exposure, product indications, and clinical trial activity. Defiance ETFs has committed to donating 100% of net advisory profits during the first two years, followed by at least 50% thereafter.
Timeline
Defiance ETFs launched the Defiance Autism Impact ETF on June 1, 2026.
The VettaFi Autism Impact Index reported a 15.84% return through August 2026.
Federal funding via the Autism CARES Act continues through 2029.
The Big Picture
The fund supplements the federal Autism CARES Act by providing private capital to the broader neurodiversity treatment market.
Investors may gain exposure to companies involved in neurodiversity research through this new ETF, while the broader sector benefits from private profit-sharing models. Individuals should consult financial advisors regarding the risks of sector-specific funds in their portfolios.
The takeaway
This launch highlights a growing convergence between socially conscious investment strategies and specialized healthcare research funding. Investors are increasingly looking to allocate capital toward companies that address significant societal costs like those associated with autism.
Further reading
For additional context on the medical and financial landscape, visit the Autism section.
Source note: This article includes information reported by ETF Trends.
Live Poll
Would you consider investing in funds that donate a portion of profits to social causes?
